Intracranial Outcomes of Ipilimumab and Nivolumab in Melanoma Brain Metastases After Progression on Anti–PD-1 Therapy
Cette étude évalue l'activité intracrânienne de l'ipilimumab-nivolumab chez des patients présentant des métastases cérébrales ayant pour origine un mélanome et montrant une progression de la maladie après un traitement par anti-PD-1
Intracranial response rates in patients with asymptomatic melanoma brain metastases (MBMs) without prior anti–programmed cell death 1 (PD-1) antibody therapy who were treated with ipilimumab-nivolumab combination range from 44% to 54%, with responders often achieving durable control. However, intracranial effectiveness of ipilimumab-nivolumab in patients with prior anti–PD-1 progression remains unknown. With increasing use of neoadjuvant and adjuvant anti-PD-1 therapy and high incidence of MBMs, clinicians will frequently encounter the challenge of managing MBMs in patients with prior anti-PD-1 exposure. We assessed the intracranial activity of ipilimumab-nivolumab in patients with MBM whose disease progressed on prior anti–PD-1 therapy.
JAMA Oncology 2024